Business Context and Reporting Period
Company: Immunovant, Inc. (IMVT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 31, 2026
Business Overview: Immunovant is a clinical-stage immunology company focused on developing IMVT-1402 (imeroprubart), a next-generation anti-FcRn inhibitor for IgG-mediated autoimmune diseases. The company discontinued the development of its first-generation asset, batoclimab, in April 2026 after Phase 3 trials for thyroid eye disease (TED) failed to meet primary endpoints. The company is now fully focused on IMVT-1402 across six indications: Graves' disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), Sjögren's disease (SjD), and cutaneous lupus erythematosus (CLE).
Key Financial Metrics
| Metric (in millions) | Fiscal 2026 | Fiscal 2025 | Change |
|---|---|---|---|
| Revenue | $0.0 | $0.0 | N/A |
| Net Loss | $(505.6) | $(413.8) | $(91.8) |
| Operating Expenses | $532.9 | $438.2 | $94.7 |
| Research & Development (R&D) | $456.7 | $360.9 | $95.8 |
| General & Administrative (G&A) | $76.2 | $77.2 | $(1.0) |
| Cash and Cash Equivalents (End of Period) | $902.1 | $714.0 | $188.1 |
| Accumulated Deficit | $(1,745.1) | $(1,239.5) | N/A |
Liquidity: As of March 31, 2026, the company held $902.1 million in cash and cash equivalents. Management expects these funds to be sufficient to fund operations through the potential commercial launch of IMVT-1402 in Graves' disease. The company raised $543.7 million in net proceeds from an underwritten common stock offering in December 2025.
Material Changes vs. Prior Period
- Strategic Pivot: In April 2026, the company announced the discontinuation of batoclimab across all indications following negative Phase 3 results in TED. This decision resulted in $39.0 million in contractual costs related to program discontinuation recognized in R&D expenses for Fiscal 2026.
- R&D Expense Increase: Total R&D expenses increased by $95.7 million year-over-year. This was driven by the $39.0 million batoclimab discontinuation charge, increased personnel costs ($17.0 million), and expanded clinical activities for IMVT-1402 in endocrine ($27.3 million increase) and rheumatology ($24.9 million increase) indications.
- Net Loss Expansion: Net loss increased by $91.8 million to $505.6 million, primarily due to the increase in operating expenses described above, partially offset by a slight increase in interest income.
- Cash Position: Cash and cash equivalents increased by $188.1 million, driven by $595.8 million in net cash provided by financing activities (primarily the December 2025 equity offering) against $407.3 million used in operating activities.
Guidance, Outlook, and Risks
Outlook: Management expects existing cash resources to fund operations through the potential commercial launch of IMVT-1402 in Graves' disease. The company anticipates continuing to incur significant losses for the foreseeable future as it advances clinical trials in six indications.
Clinical Milestones:
- GD: Two potentially registrational trials initiated; top-line results expected in calendar year 2027.
- D2T RA: Period 1 of the registrational trial completed with positive open-label data (72.7% ACR20 response at Week 16); further updates expected in H2 2026.
- CLE: Proof-of-concept trial initiated; top-line results expected in H2 2026.
- MG & CIDP: Registrational trials initiated in 2025; results expected in 2027 and 2028, respectively.
Key Risks and Contingencies:
- HanAll Agreement Dispute: The company has notified HanAll Biopharma of the decision to discontinue batoclimab. While Immunovant believes it has satisfied its obligations, HanAll may disagree, potentially leading to arbitration or litigation regarding the return of rights or milestone payments.
- Capital Requirements: The company has no committed external funding sources and will require additional capital to complete development and commercialization. Future financing may involve dilution or restrictive covenants.
- Regulatory and Clinical Risk: Success depends on the successful completion of clinical trials and regulatory approval of IMVT-1402. The company has no approved products and has never generated product revenue.
- Manufacturing Dependence: The company relies entirely on third-party contract manufacturing organizations (CMOs) for drug substance and product, exposing it to supply chain disruptions and quality control risks.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $902.1 million cash balance against the projected burn rate for six concurrent Phase 3/registrational trials.
- Batoclimab Liability: Monitor the status of negotiations with HanAll Biopharma regarding the discontinuation of batoclimab and potential financial or legal repercussions.
- IMVT-1402 Safety Profile: Confirm that IMVT-1402 continues to demonstrate the favorable safety profile (no/minimal LDL cholesterol increases) observed in Phase 1, distinguishing it from batoclimab.
- Clinical Enrollment: Track patient enrollment rates for the six ongoing indications, particularly in competitive markets like MG and CIDP.
- Equity Dilution: Assess the impact of future capital raises on existing shareholders, given the company's lack of revenue and significant operating losses.